A new trading day began on Friday, with Apellis Pharmaceuticals Inc (NASDAQ: APLS) stock price down -2.76% from the previous day of trading, before settling in for the closing price of $17.41. APLS’s price has ranged from $16.10 to $43.76 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged -21.08%. With a float of $103.61 million, this company’s outstanding shares have now reached $125.66 million.
Let’s determine the extent of company efficiency that accounts for 710 employees. In terms of profitability, gross margin is 82.94%, operating margin of -24.0%, and the pretax margin is -28.66%.
Apellis Pharmaceuticals Inc (APLS) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Apellis Pharmaceuticals Inc is 17.56%, while institutional ownership is 100.12%. The most recent insider transaction that took place on May 12 ’25, was worth 3,924,267. Before that another transaction happened on Mar 17 ’25, when Company’s VP/Chief Accounting Officer sold 183 for $24.82, making the entire transaction worth $4,543. This insider now owns 47,955 shares in total.
Apellis Pharmaceuticals Inc (APLS) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -21.08% per share during the next fiscal year.
Apellis Pharmaceuticals Inc (NASDAQ: APLS) Trading Performance Indicators
Here are Apellis Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.62. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.74.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.79, a number that is poised to hit -0.48 in the next quarter and is forecasted to reach -0.59 in one year’s time.
Technical Analysis of Apellis Pharmaceuticals Inc (APLS)
Looking closely at Apellis Pharmaceuticals Inc (NASDAQ: APLS), its last 5-days average volume was 2.26 million, which is a jump from its year-to-date volume of 2.24 million. As of the previous 9 days, the stock’s Stochastic %D was 25.77%. Additionally, its Average True Range was 0.99.
During the past 100 days, Apellis Pharmaceuticals Inc’s (APLS) raw stochastic average was set at 4.26%, which indicates a significant decrease from 28.47% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 53.60% in the past 14 days, which was lower than the 57.48% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $19.35, while its 200-day Moving Average is $28.03. However, in the short run, Apellis Pharmaceuticals Inc’s stock first resistance to watch stands at $17.30. Second resistance stands at $17.68. The third major resistance level sits at $17.98. If the price goes on to break the first support level at $16.62, it is likely to go to the next support level at $16.32. Now, if the price goes above the second support level, the third support stands at $15.94.
Apellis Pharmaceuticals Inc (NASDAQ: APLS) Key Stats
With a market capitalization of 2.13 billion, the company has a total of 125,682K Shares Outstanding. Currently, annual sales are 781,370 K while annual income is -197,880 K. The company’s previous quarter sales were 166,800 K while its latest quarter income was -92,230 K.
